epigenomics

Press release

Epigenomics AG: Dr. Uwe Staub Appointed to the Executive Board

Berlin, Germany, and U.S.A., April 03, 2013- Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that Dr. Uwe Staub, Chief Operating Officer (COO) of the Company, has been appointed to the Executive Board, effective April 1, 2013. He will join the board as a second member next to Dr. Thomas Taapken, acting CEO and CFO of Epigenomics.

Uwe Staub joined Epigenomics in November 2008 as Senior Vice President for Product Development and was promoted to COO in September 2012, when his duties were expanded to now encompass R&D, Medical and Regulatory Affairs, Customer Support and Manufacturing. He joined the Company with 14 years experience in the IVD industry in different positions in R&D and QA/RA at Abbott Diagnostics, Digene and Qiagen. He holds a Ph.D. in biochemistry from the University of Würzburg, Germany.

On his appointment Uwe Staub commented: "During recent months the Epigenomics team has achieved extremely important milestones for the future of the Company. I am honored by the appointment and look forward to help guide the Company through the next phases of its development."

"I welcome Uwe as a new member of the Executive Board. The developments in the Company over the last months have been very encouraging and exciting. I am extremely pleased to work with Uwe and the entire Epigenomics team in order to achieve our shared vision of developing Epigenomics into a commercial success story," added Thomas Taapken, acting CEO and CFO.

Heino von Prondzynski, Chairman of the Supervisory Board said: "Dr. Staub has been instrumental in the successful development of Epigenomics' products. Under his responsibility, the Company has made significant progress towards regulatory approval of Epi proColon® in the US for this convenient blood-based colorectal cancer screening assay. Given his accomplishments and experience we are convinced he is the ideal candidate to further strengthen our Executive Board."

-Ends-

Contact Epigenomics AG
Antje Zeise
Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway
Rockville, Maryland 20850
pr@epigenomics.com

About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company's products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company's technology and products have been validated through partnerships with leading diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics' legal disclaimers.*This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States of America. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the U.S.A. have not been established.